These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27523967)

  • 21. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
    Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
    Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of heterozygosity analysis in malignant gliomas.
    Mizoguchi M; Kuga D; Guan Y; Hata N; Nakamizo A; Yoshimoto K; Sasaki T
    Brain Tumor Pathol; 2011 Jul; 28(3):191-6. PubMed ID: 21629980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic, prognostic and predictive relevance of molecular markers in gliomas.
    Brandner S; von Deimling A
    Neuropathol Appl Neurobiol; 2015 Oct; 41(6):694-720. PubMed ID: 25944653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IDH1 mutations in gliomas: first series from a tertiary care centre in India with comprehensive review of literature.
    Jha P; Suri V; Sharma V; Singh G; Sharma MC; Pathak P; Chosdol K; Jha P; Suri A; Mahapatra AK; Kale SS; Sarkar C
    Exp Mol Pathol; 2011 Aug; 91(1):385-93. PubMed ID: 21569770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A surgical strategy for lower grade gliomas using intraoperative molecular diagnosis.
    Koriyama S; Nitta M; Kobayashi T; Muragaki Y; Suzuki A; Maruyama T; Komori T; Masui K; Saito T; Yasuda T; Hosono J; Okamoto S; Shioyama T; Yamatani H; Kawamata T
    Brain Tumor Pathol; 2018 Jul; 35(3):159-167. PubMed ID: 29980868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.
    Ceccarelli M; Barthel FP; Malta TM; Sabedot TS; Salama SR; Murray BA; Morozova O; Newton Y; Radenbaugh A; Pagnotta SM; Anjum S; Wang J; Manyam G; Zoppoli P; Ling S; Rao AA; Grifford M; Cherniack AD; Zhang H; Poisson L; Carlotti CG; Tirapelli DP; Rao A; Mikkelsen T; Lau CC; Yung WK; Rabadan R; Huse J; Brat DJ; Lehman NL; Barnholtz-Sloan JS; Zheng S; Hess K; Rao G; Meyerson M; Beroukhim R; Cooper L; Akbani R; Wrensch M; Haussler D; Aldape KD; Laird PW; Gutmann DH; ; Noushmehr H; Iavarone A; Verhaak RG
    Cell; 2016 Jan; 164(3):550-63. PubMed ID: 26824661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathologic features of small cell glioblastomas.
    Takeuchi H; Kitai R; Hosoda T; Yamada S; Hashimoto N; Kikuta K; Shimizu Y; Kimura H
    J Neurooncol; 2016 Apr; 127(2):337-44. PubMed ID: 26725094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress in the application of molecular biomarkers in gliomas.
    Wang J; Su HK; Zhao HF; Chen ZP; To SS
    Biochem Biophys Res Commun; 2015 Sep; 465(1):1-4. PubMed ID: 26253473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
    Ichimura K; Pearson DM; Kocialkowski S; Bäcklund LM; Chan R; Jones DT; Collins VP
    Neuro Oncol; 2009 Aug; 11(4):341-7. PubMed ID: 19435942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma.
    Ghasimi S; Wibom C; Dahlin AM; Brännström T; Golovleva I; Andersson U; Melin B
    J Neurooncol; 2016 May; 127(3):483-92. PubMed ID: 26839018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas.
    Haberler C; Wöhrer A
    Clin Neuropathol; 2014; 33(2):108-11. PubMed ID: 24559763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations.
    Ogishima T; Tamura K; Kobayashi D; Inaji M; Hayashi S; Tamura R; Nariai T; Ishii K; Maehara T
    Brain Tumor Pathol; 2017 Jan; 34(1):20-27. PubMed ID: 28251430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biphasic IDH1 phenotype in a diffusely infiltrating glioma: implications for pathogenesis, treatment and prognosis.
    Odia Y; Varma H; Tsankova NM
    Clin Neuropathol; 2015; 34(5):282-7. PubMed ID: 25907263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors.
    Sonoda Y; Yokoo H; Tanaka S; Kinoshita M; Nakada M; Nishihara H;
    Brain Tumor Pathol; 2019 Apr; 36(2):56-62. PubMed ID: 30847711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Advance of molecular subtyping and precise treatment for gliomas].
    Hua W; Mao Y
    Zhonghua Wai Ke Za Zhi; 2017 Jan; 55(1):63-66. PubMed ID: 28056258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo molecular profiling of human glioma using diffusion kurtosis imaging.
    Hempel JM; Bisdas S; Schittenhelm J; Brendle C; Bender B; Wassmann H; Skardelly M; Tabatabai G; Vega SC; Ernemann U; Klose U
    J Neurooncol; 2017 Jan; 131(1):93-101. PubMed ID: 27604789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas.
    Arita H; Ichimura K
    Brain Tumor Pathol; 2022 Jul; 39(3):121-129. PubMed ID: 35098369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bridging science and clinical practice: how to use molecular markers when caring for a patient with brain cancer.
    Rosenfeld MR
    Am Soc Clin Oncol Educ Book; 2013; ():108-13. PubMed ID: 23714471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Loss of heterozygosity on chromosomes 1 and 19 in cases of primary brain tumour].
    Born PW; Broholm H; Laursen H
    Ugeskr Laeger; 2006 Oct; 168(44):3813-6. PubMed ID: 17118240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.